Adding Talazoparib to Enzalutamide Appears Beneficial in mCRPC With HRR Mutations
Adding talazoparib to first-line treatment with enzalutamide improves rPFS in patients with HRR-deficient mCRPC, a phase 3 trial suggests.
American Society of Clinical Oncology (ASCO)
Many Patients With Locally Advanced Rectal Cancer Can Forgo Pelvic Radiation
In the phase 3 PROSPECT trial, patients with locally advanced rectal cancer had similar outcomes if they received pelvic chemoradiation or if they received FOLFOX with chemoradiation added only in select cases.
Adjuvant Osimertinib Improves OS in EGFR-Mutant, Early-Stage NSCLC
The ADAURA trial is the first global phase 3 study to show an overall survival benefit with targeted treatment in resected, EGFR-mutated, stage IB-IIIA non-small-cell lung cancer, according to study presenter Roy S. Herbst, MD, PhD.
Vorasidenib May Be New Standard Care for IDH1/2-Mutated Glioma
If approved, vorasidenib could become a new standard of care for low-grade IDH1/2-mutated gliomas, according to an ASCO discussant.
Zanidatamab Yields Durable Responses in HER2+ Biliary Tract Cancer
Zanidatamab can produce rapid and durable responses in patients with advanced HER2-positive biliary tract cancer, phase 2 data suggest.
Adding Dostarlimab to Chemotherapy Improves PFS in Endometrial Cancer
Adding dostarlimab to treatment with carboplatin and paclitaxel improves progression-free survival in advanced or recurrent endometrial cancer, the phase 3 RUBY trial suggests.
Neoadjuvant Nivolumab Plus Relatlimab Appears Safe and Effective in NSCLC
Curative surgery for non-small cell lung cancer after treatment with nivolumab plus relatlimab is as safe as surgery after nivolumab alone, the NEOpredict-Lung study suggests.
Some Patients With HER2+ Early Breast Cancer Can Safely Forgo Chemotherapy
Some patients with early HER2-positive breast cancer can safely forgo neoadjuvant chemotherapy, results of the PHERGain trial suggest.
Tucatinib Plus Trastuzumab Shows Activity in HER2+ Metastatic Biliary Tract Cancer
Treatment with tucatinib and trastuzumab elicits responses in previously treated, HER2-positive metastatic biliary tract cancer.
UCPVax Prompts Immune Responses in MGMT Unmethylated Glioblastoma
UCPVax, an anti-telomerase vaccine, has demonstrated immunogenicity in a phase 2 trial of patients with MGMT unmethylated glioblastoma.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO 2023
Loading... 
Loading...